Grufity logo
Grufity logo
VYNE

VYNE - VYNE Therapeutics Inc. Stock Price, Fair Value and News

$26.26-0.75 (-2.78%)
Delayed as of 14 Sep 2026, 04:00 pm ET

VYNE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VYNE Price Action

Last 7 days

-10.6%

Last 30 days

-36.8%

Last 90 days

4055.4%

Trailing 12 Months

8340.6%

VYNE RSI Chart

VYNE Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VYNE Valuation

Market Cap

70.1M

Price/Earnings (Trailing)

-3.05

Price/Sales (Trailing)

141.5

EV/EBITDA

-2.16

Price/Free Cashflow

-2.43

VYNE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

VYNE Fundamentals

VYNE Revenue

Revenue (TTM)

570.0K

Rev. Growth (Yr)

44.93%

Rev. Growth (Qtr)

16.28%

VYNE Earnings

Earnings (TTM)

-26.5M

Earnings Growth (Yr)

47.75%

Earnings Growth (Qtr)

16.12%

VYNE Profitability

Operating Margin

-47645.09%

EBT Margin

-4689.82%

Return on Equity

-120.04%

Return on Assets

-112.2%

Free Cashflow Yield

-41.07%

VYNE Investor Care

Shares Dilution (1Y)

575.07%

Revenue & Growth

How VYNE Therapeutics Inc. generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
2026----
2025605.0K476.0K-570.0K
2024423.0K486.0K493.0K501.0K
2023398.0K407.0K354.0K424.0K
2022879.0K710.0K744.0K477.0K
202116.0M11.0M5.9M931.0K
20201.9M13.6M16.8M21.0M
20192.8M2.0M1.2M443.0K
20184.3M4.1M3.8M3.6M
20171.1M1.6M2.3M4.6M
2016---674.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About VYNE Therapeutics Inc.

VYNE
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
 CEO
 WEBSITEvynetherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES12

VYNE Therapeutics Inc. Frequently Asked Questions

VYNE is the stock ticker symbol of VYNE Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Mon Sep 14 2026, market cap of VYNE Therapeutics Inc. is 70.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Mon Sep 14 2026, VYNE's PE ratio (Price to Earnings) is -3.05 and Price to Sales (PS) ratio is 141.5. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYNE PE ratio will change depending on the future growth rate expectations of investors.